Press releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 6, 2006Overall cardiac death rate for combined bare-metal control group equivalent to TAXUS slow- and moderate-release formulations
Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...
-
Sep 5, 2006Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population
Boston Scientific Corporation (NYSE: BSX) today announced six-month results from Phase I of its global TAXUS OLYMPIA registry,...
-
Sep 5, 2006International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of Abbott's SPIRIT II clinical trial, which reaffirmed...
-
Sep 1, 2006PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems
Boston Scientific Corporation (NYSE: BSX) today announced plans for the anticipated International launch of its PROMUS™(1) Everolimus-Eluting...
-
Aug 31, 2006Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system
Boston Scientific Corporation (NYSE: BSX) announced today that enrollment has exceeded 13,000 patients in the TAXUS OLYMPIA registry, designed to...